A 65-year-old man who was diagnosed with CLL in 2019 presented to his oncologist at routine follow-up. Medical history: type 2 diabetes controlled with insulin Patient received previous treatments with: First line: acalabrutinib (Calquence) monotherapy Achieved good clinical response over 3 yea...
In addition, it has been associated with the development of myelosuppression and secondary neoplasms; treatments are hence needed which offer greater survival and lowered toxicity. A range of new targeted agents, ibrutinib, idelalisib and venetoclax, have demonstrated such a balance in a second-line ...
” Davids, director of clinical research in the Division of Lymphoma at Dana-Farber Cancer Institute and an associate professor of medicine at Harvard Medical School in Boston, Massachusetts, told Targeted Oncology™. He detailed which ones he found to have the most impact and...
Dr Alencar on Unmet Needs Associated With BTK Inhibitor Resistance in CLL Dr Cortese on the Benefits of a Multiomic Evaluation of Immunologic Changes in CLL After Venetoclax Dr Phull on the Rationale for the Retrospective Analysis of CAR T-Cell Therapy ...
Treatments Chetomin (CTM) (Sigma-Aldrich) was dissolved in DMSO and used at concentrations 10–100 nm. Cells were pre-treated with CTM in media at 37 °C for 3 h before transferring into hypoxic conditions for a further 21 h. Alpha-cyano-4-hydroxycinnamate (Sigma-Aldrich) was dis...
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia Background New treatments have improved outcomes for patients with relapsed chronic lymphocytic leukemia (CLL), but complete remissions remain uncommon. Venetoclax has a distinct mechanism of action; it targets BCL2, a protein central...
Although future strategies and efforts with direct impact in patients care within the different systems must be considered and strategies to improve treatment access need to be implemented. The real-world evidence of the HOLA study showed disparities in patient's characteristics and treatments in Latin...
MORE ON THIS TOPIC Job Trends 6 Companies Hiring in Pennsylvania February 20, 2025 · 1 min read · Angela Gabriel Depression Supernus Falls Back on CNS Portfolio as Depression Drug Fails Mid-Stage Study February 20, 2025 · 2 min read ...
said MCL and CLL patients with the p53 mutation/17p deletion are “underserved by current standard of care treatments.” “We continue to believe that the inhibition of ROR1 with zilovertamab can play a key role in addressing important unmet medical needs in difficult-to-treat patients a...
Precision Medicine in Oncology® Sarcomas Supportive Care Spotlight - In-person and virtual events just for HCPs CME Opportunities Choose Specialty Newsletter Stay up to date on the most recent and practice-changing oncology data Subscribe Now!